An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2019
At a glance
- Drugs ADVM-022 (Primary) ; Corticosteroids
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms OPTIC
- Sponsors Adverum Biotechnologies
- 06 Jan 2019 According to an Adverum Biotechnologies media release, company will provide an update on enrollment from this trial in the first half of 2019. Interim data on the three cohorts are expected by the first quarter of 2020.
- 19 Nov 2018 According to an Adverum Biotechnologies media release,first patient has been dosed.
- 19 Nov 2018 Status changed from planning to recruiting.